リウマチ性関節炎 (Rheumatoid arthritis) とは,関節のリウマチ性関節炎 (Rheumatoid arthritis) とは,関節のリウマチ性関節炎 (Rheumatoid arthritis)
David L Scott1, Frederick Wolfe, Tom W J Huizinga
1Department of Rheumatology, King's College London School of Medicine, London, UK. d.scott@nhs.net
Lancet (London, England)
|September 28, 2010
まとめ
リウマチ性関節炎は,持続的な炎症と自己抗体を含み,遺伝と喫煙が主要な危険因子である. DMARDsや生物学的剤のような効果的な治療法は,炎症をコントロールし,関節損傷を予防することを目的としています.
科学分野:
- レウマトロジーの病理学
- 免疫学 免疫学とは
- 遺伝学 遺伝学とは
背景:
- リウマチ性関節炎 (RA) は,神経炎,全身性炎症,自己抗体によって特徴づけられる慢性自己免疫疾患です.
- 遺伝的要因は,RAリスクの50%を占め,喫煙が主な環境的トリガーである.
- RAは先進国の成人の0.5-1.0%に影響し,主に女性や高齢者が関節損傷や併発症を引き起こす.
研究 の 目的:
- リウマチ性関節炎の特徴,危険因子,および現在の治療戦略を概説する.
- RAの管理における疾患変容性抗レウマティック薬 (DMARDs) と生物学的薬剤の役割について議論する.
- ターゲットを絞り,集中的な治療を通じて長期的な寛解を達成するという究極の目標を強調すること.
主な方法:
- リウマチ性関節炎の病理生理学と治療に関する既存の文献のレビュー.
- RAの有病率と発生率に関する疫学データの分析.
- DMARDsと生物学的治療法のメカニズムと臨床応用についての議論.
主要な成果:
- リウマチ性関節炎は,障害と生活の質の低下の重要な原因であり,心血管疾患のリスクの増加と関連しています.
- メソトレクサートは主要なDMARDであり,しばしば組み合わせ療法で使用されます.
- TNF阻害剤,アバタセプト,リトゥキシマブ,トシリズマブを含む生物学的薬剤は,耐火性RAに有効ですが,感染リスクとコストのために制限に直面しています.
結論:
- リウマチ性関節炎の効果的な管理には,関節炎と全身性炎症をコントロールして,関節損傷を予防し,患者のアウトカムを改善する必要があります.
- バイオマーカーによって導かれた標的治療法の開発は,関節リウマチ症の長期的な寛解を達成する見込みです.
- 治療の有効性と安全性,コストのバランスをとることは,先進的なRA治療法の広範な適用に不可欠です.
関連する概念動画
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...